Inhibition of 5-lipoxygenase downregu... - Advanced Prostate...

Advanced Prostate Cancer

21,806 members27,295 posts

Inhibition of 5-lipoxygenase downregulates stemness ...

pjoshea13 profile image
0 Replies

New paper below.

{Coincidentally, AlexPaulsen posted a 2011 paper by this team yesterday.}

"The cancer stem cell (CSC) concept suggests that neoplastic clones are maintained exclusively by a rare group of cells possessed with stem cell properties. CSCs are characterized by features that include self-renewal, pluripotency and tumorigenicity, and are thought to be solely responsible for tumor recurrence and metastasis. A hierarchically organized CSC model is becoming increasingly evident for various types of cancer, including prostate cancer. The CD44 (+), CD133 (+) cell subpopulations were isolated from human prostate tumors which exhibit stem-like properties showing therapeutic-resistance, capacity of self-renewal, and exact recapitulation of the original tumor in vivo. Thus, an important challenge is to find measures to eliminate these cancer stem cells, which will stop tumor growth and prevent disease-recurrence. However, knowledge about molecular features critical for the survival of prostate cancer stem cells (PCSC) is meager. Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591 dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential role in the survival of PCSC."

-Patrick

ncbi.nlm.nih.gov/pubmed/307...

Oncotarget. 2019 Jan 11;10(4):424-436. doi: 10.18632/oncotarget.13422. eCollection 2019 Jan 11.

Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase.

Sarveswaran S1, Varma NRS1, Morisetty S1, Ghosh J1.

Author information

Abstract

The cancer stem cell (CSC) concept suggests that neoplastic clones are maintained exclusively by a rare group of cells possessed with stem cell properties. CSCs are characterized by features that include self-renewal, pluripotency and tumorigenicity, and are thought to be solely responsible for tumor recurrence and metastasis. A hierarchically organized CSC model is becoming increasingly evident for various types of cancer, including prostate cancer. The CD44 (+), CD133 (+) cell subpopulations were isolated from human prostate tumors which exhibit stem-like properties showing therapeutic-resistance, capacity of self-renewal, and exact recapitulation of the original tumor in vivo. Thus, an important challenge is to find measures to eliminate these cancer stem cells, which will stop tumor growth and prevent disease-recurrence. However, knowledge about molecular features critical for the survival of prostate cancer stem cells (PCSC) is meager. Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591 dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential role in the survival of PCSC. Interestingly, MK591 treatment decreases protein levels and inhibits transcriptional activities of Nanog and c-Myc. Since Nanog and c-Myc play important roles as stemness factors, our findings indicate that the 5-Lox activity plays a causal role in maintaining prostate cancer stemness via regulation of Nanog and c-Myc, and suggest that further exploration of 5-Lox-mediated signaling in PCSC may lead to development of novel, target-based, durable strategies to effectively block development and growth of prostate tumors, and prevent prostate cancer recurrence.

KEYWORDS:

5-lipoxygenase; MK591; apoptosis; c-Myc; prostate cancer stem cells

PMID: 30728896 PMCID: PMC6355185 DOI: 10.18632/oncotarget.13422

Written by
pjoshea13 profile image
pjoshea13
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Effects of Omega 3 (let me remind you that walnuts have more omega 3 than fish) on cancer. Still preclinical.

Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in...

List of drugs by their metastatic prostate cancer cancer fighting properties

I asked ChatGPT to put the following drugs in order of their metastatic prostate cancer cancer...

Liquid Biopsy Method Enables Real-Time Monitoring of Metastatic Prostate Cancer…

….and can help in finding new targets for therapies!...

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage...

Ivermectin for Cancer

I picked up a little Ivermectin for its possible anti-Covid-19 properties. Maybe I should take it...